Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 581-88-4
2. Debrisoquine Sulfate
3. Declinax
4. Isocaramidine Sulfate
5. Equitonil
6. Debrisoquin Sulfate [usan]
7. Debrisoquin Hemisulfate
8. Debrisoquinsulfate
9. Debrisoquine Sulphate
10. Debrisoquin Sulphate
11. Debrisoquin (sulfate)
12. Ro 5-3307/1
13. 2(1h)-isoquinolinecarboximidamide, 3,4-dihydro-, Sulfate (2:1)
14. Q94064n9nw
15. Nsc-139330
16. 3,4-dihydro-2(1h)-isoquinolinecarboxamidine Sulfate (2:1)
17. Debrisoquine Sulfate; Isocaramidine Sulfate
18. Pasiron-t
19. 1,2,3,4-tetrahydro-isoquinoline-2-carboxamidine Sulfate
20. Debrisoquin Sulfate (usan)
21. Dsstox_cid_27755
22. Dsstox_rid_82532
23. Dsstox_gsid_47775
24. 3,4-dihydro-1h-isoquinoline-2-carboximidamide;sulfuric Acid
25. Chebi:50973
26. Ro 5-3307
27. Ncgc00016513-01
28. Cas-581-88-4
29. Einecs 209-472-4
30. Nsc 139330
31. Unii-q94064n9nw
32. Declinax (tn)
33. Prestwick_690
34. Schembl122316
35. Chembl1593558
36. Debrisoquin Sulfate [mi]
37. Dtxsid2047775
38. Hms1569k05
39. Hms2096k05
40. Hms3713k05
41. Tox21_110468
42. Debrisoquine Sulfate [mart.]
43. Mfcd00941496
44. Debrisoquine Sulfate [who-dd]
45. Akos026751495
46. Tox21_110468_1
47. Ccg-220372
48. Ncgc00016513-05
49. As-16854
50. Ft-0665523
51. Ro-5-3307/1
52. D03664
53. Sr-01000872657
54. Sr-01000872657-1
55. 3,4-dihydro-2(1h)-isoquinolinecarboxamide Hemisulfate
56. Q27122265
57. 3,4-dihydroisoquinoline-2(1h)-carboximidamide Hemisulfate
58. 3,4-dihydro-2(1h)-isoquinolinecarboxamidine Sulphate (2:1)
59. 2(1h)-isoquinolinecarboximidamide, 3,4-dihydro-, Sulphate (2:1)
| Molecular Weight | 448.5 g/mol |
|---|---|
| Molecular Formula | C20H28N6O4S |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | 448.18927457 g/mol |
| Monoisotopic Mass | 448.18927457 g/mol |
| Topological Polar Surface Area | 189 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 284 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
ABOUT THIS PAGE
A Debrisoquin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Debrisoquin, including repackagers and relabelers. The FDA regulates Debrisoquin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Debrisoquin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Debrisoquin supplier is an individual or a company that provides Debrisoquin active pharmaceutical ingredient (API) or Debrisoquin finished formulations upon request. The Debrisoquin suppliers may include Debrisoquin API manufacturers, exporters, distributors and traders.
click here to find a list of Debrisoquin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Debrisoquin DMF (Drug Master File) is a document detailing the whole manufacturing process of Debrisoquin active pharmaceutical ingredient (API) in detail. Different forms of Debrisoquin DMFs exist exist since differing nations have different regulations, such as Debrisoquin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Debrisoquin DMF submitted to regulatory agencies in the US is known as a USDMF. Debrisoquin USDMF includes data on Debrisoquin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Debrisoquin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Debrisoquin suppliers with USDMF on PharmaCompass.
Debrisoquin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Debrisoquin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Debrisoquin GMP manufacturer or Debrisoquin GMP API supplier for your needs.
A Debrisoquin CoA (Certificate of Analysis) is a formal document that attests to Debrisoquin's compliance with Debrisoquin specifications and serves as a tool for batch-level quality control.
Debrisoquin CoA mostly includes findings from lab analyses of a specific batch. For each Debrisoquin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Debrisoquin may be tested according to a variety of international standards, such as European Pharmacopoeia (Debrisoquin EP), Debrisoquin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Debrisoquin USP).
LOOKING FOR A SUPPLIER?
